Overview

This trial is active, not recruiting.

Conditions non-hodgkin's lymphoma (nhl), chronic lymphocytic leukemia (cll), multiple myeloma (mm)
Sponsor iOMEDICO AG
Start date April 2009
End date August 2019
Trial size 3750 participants
Trial identifier NCT00889798, IOM-TLN

Summary

The purpose of this registry is to record information on therapy reality of malignant lymphatic systemic diseases by office-based haematologists in Germany.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective

Primary Outcomes

Measure
Documentation of anamnestic data and therapy sequences
time frame: 5 years per patient

Secondary Outcomes

Measure
Documentation of response rates and progression-free survival per therapy sequence, overall survival time and adverse reactions
time frame: 5 years per patient

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Confirmed diagnosis of Non-Hodgkin`s lymphoma, chronic lymphocytic leukaemia or multiple myeloma - Must receive a first- or second-line therapy - 18 years or older - Signed, written informed consent Exclusion Criteria: - no systemic therapy

Additional Information

Official title Epidemiological Registry Describing Treatment Reality and Therapy Modalities of Patients With Malignant Lymphatic Systemic Diseases (Non-Hodgkin`s Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma) Requiring Therapy.
Description The TLN is a prospective, longitudinal, nation wide cohort study with the purpose to record information on the antineoplastic treatment of lymphatic neoplasms in Germany. The registry will follow patients for up to five years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. The impact of nutrition (LyNut) and physical activity (LyNut) on the course of the adjuvant disease will be examined in patients with indolent and aggressive Non-Hodgin Lymphoma, as well as long-term effects of systemic treatment (LyTox) and quality of life (LyLife) in patients with multiple myeloma.
Trial information was received from ClinicalTrials.gov and was last updated in June 2016.
Information provided to ClinicalTrials.gov by iOMEDICO AG.